Fernando

Antiretroviral drug interactions decline, but clinical screening for drug interactions remains important

New BC-CfE research, published in the recent issue of AIDS, characterizes trends in the annual prevalence of drug interactions between antiretroviral therapy (ART) and other non-antiretroviral medications in relation to ART prescribing patterns. The study also describes drug interaction-related ART changes.

Antiretroviral drug interactions decline, but clinical screening for drug interactions remains important Read More »

Effects of Treatment as Prevention¨ evaluated in first of its kind analysis

In what’s believed to be a first of its kind analysis, BC-CfE researchers evaluated patient reported HIV care experiences and therapeutic outcomes prior to, and after, implementation of BC’s Treatment as Prevention¨ (TasP¨) designed Seek and Treat for Optimal Prevention of HIV/AIDS (STOP HIV/AIDS) program.

Effects of Treatment as Prevention¨ evaluated in first of its kind analysis Read More »

BC-CfE researchers present their findings at CAHR 2022

In late April the Canadian Association for HIV Research (CAHR) held its annual conference. With more than 1,000 members, CAHR is the leading organization of HIV/AIDS researchers in Canada. The theme for this year’s virtual conference was “Striving Towards Equity and Flourishing in the HIV Response”. In choosing the theme, organizers of the conference compared the decades-long fight for equitable distribution of antiretroviral therapy (ART) to the distribution of COVID-19 vaccines, and the massive disparities seen between high and low-income countries in both.

BC-CfE researchers present their findings at CAHR 2022 Read More »

Treatment Optimization of Psychosis (TOP) and how BC is improving care for those living with schizophrenia

Schizophrenia affects more than 24 million people worldwide according to the World Health Organization. Common symptoms include thinking disorder, delusions, hallucinations, and negative syndrome, which induces severe loss of interest and social isolation. The term schizophrenia literally means “a splitting of the mind” and was coined in 1908 by Swiss psychiatrist Dr. Paul Eugen Bleuler.

Treatment Optimization of Psychosis (TOP) and how BC is improving care for those living with schizophrenia Read More »

BC-CfE urges heightened caution due to monkeypox

Health authorities in Canada, the US, Spain, Portugal, and the UK have issued alerts over possible outbreaks of monkeypox. This viral infection is usually spread by respiratory transmission, but in these latest cases certain characteristics point towards fluid contact as a possible mode of transmission. A majority of these monkeypox cases are among men who have sex with men.

BC-CfE urges heightened caution due to monkeypox Read More »

Chapter 1: Pre-HAART (1992 – 1996)

In the 30 years since its inception in 1992, the advancements made by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) have transformed HIV from a rapidly fatal disease, to a chronic and manageable illness that is highly, and easily, preventable. By helping shape local and global policy with its Treatment as Prevention¨ strategy, the BC-CfE has quite literally revolutionized HIV/AIDS care, saving and improving millions of lives worldwide.

Chapter 1: Pre-HAART (1992 – 1996) Read More »

Scroll to Top

Canada Post has provided notification of restarting their operations on December 17, 2024. As Canada Post ramps up and stabilizes their services, the BC-CfE will continue the following measures on an interim basis to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory will utilize private courier for delivery of outgoing reports and documents. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy will utilize private courier for delivery of medications. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)